Affimed NV at Citi Immuno-Oncology Summit (Virtual) Transcript
Okay. Great. Welcome back everyone to Citi's IO Summit for 2022. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi. I think most of you know me. If you do have questions for the management team, you can just e-mail me, [email protected] and I will relay those questions to the management team.
So with that, it's my pleasure to introduce from Affimed, the CEO, Adi Hoess as well as the CMO, Andreas Harstrick. I welcome both of you. So Adi, maybe as a starting point, it would be great, if you could just do a general introduction to the company for those that are less familiar with the story, just explaining how the innate cell engager platform is differentiated from competing approaches in the NK cell engager space. Yigal, thanks a lot for the introduction. Just sorry about that.
So I'm also happy to welcome everybody joining this video conference. Quite excited to be able to present to you about
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |